Drugs / mRNA-0217/S001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05916248 | Dec 2023 → Jun 2026 overdue | neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-0217/S001 | “Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pembrolizumab in Patients With Advanced Solid Tumors” NCT05916248 ↗ |
| Modality | Messenger RNA (mRNA) | “Personalized mRNA-0217 Vaccines” NCT05916248 ↗ |